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Micafungina como profilaxis antifúngica en 
pacientes hematológicos no trasplantados
RESUMEN
Introducción. Las infecciones fúngicas son una im-
portante causa de morbilidad y mortalidad en los pacien-
tes hematológicos. Estas infecciones son principalmente 
debidas a Candida spp.y Aspergillus spp. La mortalidad 
debida a estas infecciones es alta, pero ha descendido a 
lo largo de las últimas series gracias a los mejores agentes 
antifúngicos. Las equinocandinas son, in vitro, muy acti-
vas contra Candida y Aspergillus spp. El objetivo de este 
estudio es analizar la eficacia y seguridad de micafungina 
en la profilaxis antifúngica de pacientes hematológicos en 
tratamiento quimioterápico. 
Material y métodos. Un estudio multicéntrico, ob-
servacional, retrospectivo se llevó a cabo en 7 servicios de 
Hematología en España. Se incluyeron los pacientes ingre-
sados con quimioterapia o tratamiento inmunosupresor 
que hubieran recibido micafunfina como profilaxis entre 
el 1 de enero de 2009 y el 31 de diciembre de 2014. 
Resultados. Hubo 5 casos de infección fúngica pro-
bable o probada (4,8%) según los criterios de la EORTC 
de 2008: 2 probadas, 3 probables. Las infecciones fúngi-
cas fueron 3 aspergilosis y 2 candidiasis. No hubo ningún 
abandono de la profilaxis con micafungina debido a toxi-
cidad. 
Conclusión. Micafungina es un agente antifúngico 
que, usado en profilaxis, ha demostrado buena eficacia y 
excelente perfil de toxicidad, siendo una opción interesan-
te en pacientes que requieren profilaxis antifúngica du-
rante su hospitalización. 
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ABSTRACT
Introduction. Fungal infections are a major cause of 
morbidity and mortality in the haematological patients. These 
infections are mainly due to Candida spp. and Aspergillus spp. 
Mortality by these infections is high, but rates have descended 
in the latest series due to better antifungal agents. Echinocan-
dins are, in vitro, very active against Candida and Aspergillus 
spp. The objective of the study is to analyse the efficacy and 
safety of micafungin in the antifungal prophylaxis of haema-
tological patients on chemotherapy. 
Material and methods. A multicentre, observational 
retrospective study was performed in 7 Haematology Depart-
ments in Spain. Patients admitted to these departments with 
chemotherapy or immunosuppressive treatment, and who had 
received antifungal prophylaxis with micafungin between 1 
January 2009 and 31 December 2014 were included. 
Results. There were 5 cases of probable or proven fun-
gal infection (4.8%) according to the 2008 EORTC criteria: 2 
proven, 3 probable. The types of fungal infection were 3 as-
pergillosis and 2 candidiasis. There were no drop-outs from the 
prophylaxis with micafungin due to toxicity. 
Conclusion. Micafungin is an antifungal agent which, 
used in prophylaxis, has demonstrated good efficacy and an 
excellent toxicity profile, making it an apparently interesting 
option in patients requiring antifungal prophylaxis during 
their hospitalisation episode. 
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fungal prophylaxis of haematological patients on chemother-
apy. 
MATERIAL AND METHODS
A multicentre, observational retrospective study was 
performed in 7 Haematology Departments in Spain. All the 
patients admitted to these departments that had received 
chemotherapy or immunosuppressive treatment for their hae-
matological disease and who had received antifungal proph-
ylaxis with micafungin over 5 consecutive days in the period 
comprised between 1 January 2009 and 31 December 2014 
were included. Each patient’s observation period ended when 
they were discharged for any reason. Micafungin was adminis-
tered intravenously at a dose of 50 mg a day.
The data were obtained from the patients’ health history 
by means of a case report form (CRF) requested from the Alce 
Ingenieria company, whereas the SPSS statistical application 
was used for the statistical analysis. 
The possible, probable or proven fungal infection criteria 
were consistent with those described by the Invasive Fungal 
Infections Cooperative Group of the European Organization 
for Research and Treatment of Cancer (EORTC) of 2008 [27]. 
The objective was to analyse the efficacy and safety of mi-
cafungin in the antifungal prophylaxis of haematological pa-
tients on chemotherapy. The efficacy of antifungal prophylaxis 
was defined as the absence of diagnosed or suspected fungal 
infection during the prophylaxis period with micafungin. For 
this purpose, the daily dose used, the days of prophylaxis, the 
reason for the end of treatment, the need to change the an-
ti-fungal agent or the dose of micafungin, the reasons for the 
change, as well as the results of the different diagnostic tests 
performed such as cultures, serologies or radiological tests, 
were analysed. With regard to safety, micafungin’s tolerabili-
ty and safety were analysed on the basis of adverse reactions 
recorded in the medical history as being attributable to the 
treatment with micafungin, as well as the degree of the ad-
verse reaction. 
RESULTS
A total of 104 episodes corresponding to 89 haematolog-
ical patients from 7 hospitals in Spain were analysed. The pa-
tients’ baseline characteristics can be observed in table 1. The 
median patient age was 59 years (range 19-84), 55 were men 
and 34 were woman. The patients presented the following 
haematological diseases: Forty-three episodes of acute mye-
loid leukaemia (41.3%), thirty-one episodes of acute lymph-
oblastic leukaemia (29.8%), ten episodes of lymphoma (9.6%), 
nine episodes of aplastic anemia (8.7%) and eleven episodes of 
other haematological conditions (10.6%). The median of days 
of hospitalisation for the episodes was 31.5 days. In 63 epi-
sodes reported (60.6%), micafungin was given as prophylaxis 
following the diagnosis. It should be emphasised that in 19 ep-
isodes (18.3%), the patients were in relapse, partial response 
INTRODUCTION
Fungal infections are a major cause of morbidity and mor-
tality in haematological patients, particularly in at high risk 
of fungal infection patients [1, 2]. The increase in the number 
of individuals with some type of immunosuppression, is the 
most important cause in the increase of this type of infections. 
Approximately 10% -50% of haematological patients with 
marked neutropenia or recipients of a haematopoietic stem 
cell transplant have an episode of Invasive Fungal Infection 
(IFI) during the evolution of their disease. These infections are 
mainly due to Candida spp. and Aspergillus spp. [2-4]. Mor-
tality by these infections is usually high, due to the difficulty 
involved in making an early diagnosis. Fortunately, mortality 
rates for aspergillosis have gradually descended in the latest 
series and this is fundamentally due to two important break-
throughs. On the one hand, the improvement in early diag-
nostic techniques, such as galactomannan, aspergillus PCR and 
imaging techniques. On the other hand, the advent of antifun-
gal agents with greater efficacy and good tolerance used for 
prophylactic, empirical, pre-emptive and targeted treatment 
[5, 6]. Echinocandins are very active in vitro against Candida 
and Aspergillus spp. [7], which have proven their efficacy in 
the prophylaxis of fungal infection [8]. Micafungin, as opposed 
to the other echinocandins, presents a better activity against 
certain strains of Candida spp., classically Candida glabrata [7, 
9] and also against Aspergillus spp. [8, 10]. It has a low poten-
tial for drug interactions [11-14], which could make it inter-
esting in the case of patients requiring concomitant medica-
tion and it can be given to patients with moderate liver failure 
in whom the azoles, the reference drugs in prophylaxis, have 
certain limitations [15]. This is why there are consensus-based 
documents that point to the advantages of this drug in proph-
ylaxis [16]. There is published experience with micafungin in 
the primary prophylaxis of haematological patients in the con-
text of haematopoietic stem cell transplant and acute myeloid 
leukaemias induction therapy [17, 18]. International guidelines 
provide a recommendation for micafungin, both in prophylaxis 
and in the treatment of the candidiasis [4, 19-21]
Some Spanish centres have accumulated experience in 
primary prophylaxis with micafungin in patients admitted 
to haematology departments undergoing chemotherapy in 
whom a prolonged period of neutropenia is expected and in 
whom azoles might constitute a problem of tolerability due to 
drug interactions, liver alterations, long QT syndrome or intol-
erance. There is a great deal of experience published with mi-
cafungin in the antifungal prophylaxis of patients undergoing 
haematopoietic stem cell transplant [22-26]. However, experi-
ence is more limited in non-transplanted patients. Therefore, 
the evaluation of the efficacy and safety of antifungal proph-
ylaxis with micafungin in haematological patients undergo-
ing chemotherapy is an interesting area of investigation, and 
therefore we are proposing a retrospective analysis of patients 
undergoing chemotherapy who have received prophylactic an-
tifungal treatment with micafungin. The objective of the study 
is to analyse the efficacy and safety of micafungin in the anti-
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probable aspergillosis and 2 proven candidiasis. The data are 
shown in table 4. Of the 26 patients that needed to start em-
pirical antifungal treatment or a change of antifungal, proba-
ble or proven fungal infection according to the EORTC criteria 
was only confirmed in 5 cases (19.2%). In other words, 80,8% 
of the patients who were switched from micafungin to other 
antifungals did not ultimately develop an IFI. Twelve (11.7%) 
of the 89 patients recruited to the study died, although only 
2 of them were diagnosed with fungal infection. 88.3% of the 
cases were discharged due to clinical improvement. 
or resistant; in other words, with uncontrolled haematological 
disease. 
In most of the episodes (95) micafungin was the selected 
drug as prophylaxis because of the center practice. Some of 
the other reasons for the choice were drug interactions with 
the use of other antifungals (4), liver dysfunctions (15), severe 
mucositis (7) or long QT syndrome (1). The results are displayed 
in greater detail in table 2.
The median days of use of micafungin was 18 days (range 
5-384) at a dose of 50 mg/day. We have data from 101 of the 
104 episodes with regard to the reason for the end of proph-
ylaxis. There were no drop-outs from the prophylaxis with 
micafungin due to toxicity, and the prophylaxis was finished 
when the neutropenia period ended in 64.4% of the cases. 
Empirical antifungal treatment was initiated in 19 episodes 
(18.8%), the antifungal was changed on 7 occasions, and in 10 
cases the prophylaxis was finished for other reasons .The data 
are shown in table 3. 91 of the 104 episodes (87.5%) presented 
neutropenia (<500 neutrophils/mm3), with a median duration 
of 22 days. There were 59 episodes of fever (56.7%) and 45 
episodes (43.3%) without fever during hospitalisation. There 
were 5 cases of probable or proven fungal infection (4.8%) ac-
cording to the 2008 EORTC criteria: 2 proven and 3 probable. 
We have eliminated 4 possible fungal infections because prob-
ably there are not an IFI. The types of fungal infection were 3 
Age [median (range)]: 59 years (19-84 years)
Sex
Male: 55 patients (61.8%)
Female: 34 patients (38.2%)
Haematological disease
Acute myeloblastic leukaemia: 43 episodes (41.3%)
Acute lymphoblastic leukaemia: 31 episodes (29.8%)
Lymphoma: 10 episodes (9.6%)
Bone marrow aplasia: 9 episodes (8.7%)
Others: 11 episodes (10.6%)
Situation of the disease
Diagnosis: 63 patients (60.6%)
Complete remission: 20 patients (19.2%)
Partial response: 7 patients (6.7%)
Relapse: 11 patients (10.6%)
Salvage: 0 patients (0%)
Resistant: 1 patient (1%)
Unknown: 2 patients (1.2%)
Total: 104 episodes
Days´ hospitalisation: 31.5 days (range 4-451)
Table 1  Patients’ baseline and 
demographic characteristics
Prophylaxis 95  
Protocol 13 
Failure of previous antifungal 2 
Limiting drug interactions 4 
Liver dysfunctions 15 
Severe mucositis 7 
Long QT syndrome 1 
Other reason 31 
Table 2  Reasons for the use of micafungin. 
(More than one reason could be 
chosen).
End of prophylaxis 65 (64.4%)
Adverse reaction 0 (0%)
Empirical treatment 19 (18.8)
Change of antifungal 7 (6.9%)
Other 10 (9.9%)
Total 101 evaluable episodes
Table 3  Reasons for ending prophylaxis 
with micafungin in 101 of the 104 
total episodes.
Table 4  Development of fungal infection
EORTC : European Organization for Research and Treatment of Cancer
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